Wolverine Stack (BPC-157 + TB-500) 20mg
A dual-action preclinical blend pairing BPC-157 and TB-500 in equal ratios to investigate soft tissue regeneration and cellular repair pathways.
Mechanism
BPC-157 stimulates VEGFR2-mediated angiogenesis and tissue cytoprotection, while TB-500 sequesters actin to accelerate cellular migration and extracellular matrix remodeling during tissue repair.
Dosing
Standard laboratory conventions describe a starting reference dose of approximately 250 mcg of each peptide delivered subcutaneously via 5 units on a standard U-100 syringe.
Reconstitution
Introducing 2.0 mL of bacteriostatic water into a 20 mg blend vial yields a total peptide concentration of 10 mg/mL, delivering 5 mg/mL of BPC-157 and 5 mg/mL of TB-500.
Storage
Store the unmixed lyophilized vial shielded from light at cool temperatures, and keep the reconstituted solution refrigerated between 2°C and 8°C for use within a few weeks.
Mix & measure Wolverine Stack (BPC-157 + TB-500) 20mg
Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.
Mix & measure Wolverine Stack (BPC-157 + TB-500) 20mg
Vial strength → BAC water → target dose
Common vial sizes
Label claim
Total doses in vial: 80.0
U-100 syringe: 100 units = 1 mL
Need supplies for this protocol?
Research-grade peptides, fast shipping, competitive pricing
Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →
Track my protocol
Log each dose, build a streak, and watch your progress through this protocol's schedule.
Dosing Chart
| Phase / Day(s) | Dose & Frequency | Volume (U-100 units / mL) |
|---|---|---|
| Loading (Weeks 1–4) | ~500 mcg BPC-157 + ~500 mcg TB-500 daily | 10 units (0.10 mL) |
| Maintenance (Weeks 5–8) | ~250 mcg BPC-157 + ~250 mcg TB-500 daily | 5 units (0.05 mL) |
| Lower Reference | ~250 mcg of each, reduced weekly frequency | 5 units (0.05 mL) |
Reconstitution Steps
- 1
Sanitize the rubber stoppers of both the Wolverine stack vial and the bacteriostatic water vial using sterile alcohol swabs.
- 2
Draw 2.0 mL of bacteriostatic water using an appropriate sterile syringe.
- 3
Insert the needle into the blend vial and release the diluent down the glass interior wall to prevent direct impact onto the lyophilized cake.
- 4
Swirl the vial gently until the powder completely dissolves without shaking, yielding a clear solution of 5 mg/mL per peptide.
- 5
Date the vial and immediately place it into refrigerated storage between 2°C and 8°C.
Supplies Needed
Peptide Vial
Lyophilized Wolverine stack containing 10 mg BPC-157 and 10 mg TB-500 (20 mg total)
Insulin Syringes (U-100)
Accurately measuring and dispensing fractional milliliter volumes for research administration
Bacteriostatic Water
Sterile diluent containing 0.9% benzyl alcohol used to reconstitute the lyophilized powder
Alcohol Swabs
Disinfecting vial septums and preparation surfaces prior to needle penetration
Why researchers study it
Tendon, ligament, and musculoskeletal soft-tissue repair
Gastrointestinal mucosal cytoprotection and fistula healing
Endothelial cell migration and neovascularization kinetics
These describe what is being studied, not proven benefits, approved uses, or promised results.
Overview
The Wolverine stack is an informal research designation for a combined formulation of BPC-157 and TB-500, synthesized at an equivalent 1:1 milligram proportion. Named colloquially after fictional rapid healing capabilities, this combination aims to leverage the cytoprotective and angiogenic properties of BPC-157 alongside the actin-regulating and migratory dynamics attributed to the thymosin beta-4 fragment, TB-500. It is engineered specifically for laboratory exploration into complex wound-healing cascades. Because this formulation is pre-mixed into a single lyophilized matrix, both peptides are co-administered at an identical mass ratio. While individual preclinical rodent models demonstrate significant tissue-repair activity for both agents independently, no controlled clinical trials have formally evaluated the safety, pharmacokinetics, or therapeutic outcomes of this specific dual blend. Consequently, data regarding theoretical synergistic interactions remain purely unverified scientific hypotheses. Investigators utilizing this compound primarily explore multi-tissue healing models, spanning tenocyte migration, angiogenesis, and gastrointestinal protection. All documentation surrounding administration schedules relies on community extrapolations and laboratory convention rather than validated human clinical parameters.
References
- 1.Sikirić P, et al., Curr Pharm Des, 2011 — Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract
- 2.Chang CH, et al., J Appl Physiol, 2011 — BPC 157 promotes tendon healing via tendon outgrowth, fibroblast survival and cell migration
- 3.Gwyer D, Wragg NM, Wilson SL, Cell Tissue Res, 2019 — Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing
- 4.Goldstein AL, Hannappel E, Kleinman HK, Trends Mol Med, 2005 — Thymosin β4: actin-sequestering protein moonlights to repair injured tissues
- 5.Malinda KM, et al., J Invest Dermatol, 1999 — Thymosin β4 accelerates wound healing
- 6.Crockford D, et al., Ann N Y Acad Sci, 2010 — Thymosin β4: structure, function, and clinical applications
Supplies Needed
Suggested supplier
Research use only. Listing a supplier is not an endorsement of any protocol on this site, and nothing sold there is approved for human use.
Related protocols
View allHGH 191AA 10 IU
Recombinant 191-amino-acid human growth hormone sequence evaluated for endocrine signaling, lipolysis, and lean tissue preservation.
View ProtocolCJC-1295 DAC 2mg
Long-acting GHRH synthetic analog bound to albumin via DAC to sustain continuous GH and IGF-1 elevation in research models.
View ProtocolThymosin Alpha-1 5mg
Thymosin Alpha-1 is a 28-amino-acid peptide studied for T-cell maturation, dendritic function, and immune system modulation.
View Protocol